BMO Capital initiated coverage of BrightSpring Health (BTSG) with an Outperform rating and $40 price target BMO Capital sees a long runway for BrightSpring to sign additional limited distribution drug contracts while also benefiting from more generic conversions, which coupled with opportunities on the Provider Services side, support the firm’s three-year 12%+ EBITDA growth outlook, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health Services, Inc.: Strong Growth Potential and Buy Rating Affirmed by BMO Capital
- BrightSpring Health price target raised to $39 from $33 at Wells Fargo
- BrightSpring Health price target raised to $40 from $32 at Morgan Stanley
- BrightSpring Health Services Shines in Q3 Earnings Call
- BrightSpring Health price target raised to $38 from $32 at Mizuho